• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    PerkinElmer Announces Financial Results for the Third Quarter of 2022

    11/8/22 6:00:00 AM ET
    $PKI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $PKI alert in real time by email
    • Third quarter revenue of $712 million; (17)% reported growth
    • Pro forma* total revenue of $1,033 million; 9% pro forma non-COVID organic growth
    • Third quarter GAAP EPS from continuing operations of $0.55; pro forma adjusted EPS of $1.51
    • Initiates fourth quarter and updates full year pro forma guidance

    PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today reported financial results for the third quarter ended October 2, 2022.

    The Company reported GAAP earnings per share from continuing operations of $0.55, as compared to GAAP earnings per share from continuing operations of $0.94 in the same period a year ago. GAAP revenue for the quarter was $712 million, as compared to $861 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $111 million, as compared to $196 million for the same period a year ago. GAAP operating profit margin was 15.6% as a percentage of revenue, as compared to 22.7% in the same period a year ago.

    Adjusted operating income from continuing operations was $224 million, as compared to $322 million for the same period a year ago. Adjusted operating profit margin was 31.4% as a percentage of revenue, as compared to 37.4% in the same period a year ago.

    Pro forma adjusted earnings per share for the quarter was $1.51, as compared to $2.31 in the same period a year ago. Pro forma adjusted revenue for the quarter was $1.03 billion, as compared to $1.17 billion in the same period a year ago. Pro forma adjusted operating income for the quarter was $272 million, as compared to $359 million for the same period a year ago. Pro forma adjusted operating profit margin was 26.3% as a percentage of adjusted revenue, as compared to 30.8% in the same period a year ago.

    Adjustments for the Company's non-GAAP financial measures have been noted in the attached reconciliations.

    *Pro forma information includes results from the Applied, Food and Enterprise Services ("AES") businesses currently held for sale.

    "It was great to see how we continued to execute at a high level across the company in the quarter, both operationally and financially," said Prahlad Singh, president and chief executive officer of PerkinElmer. "The energy and excitement amongst our employees in all our businesses remains exceptional as we continue to prepare for the upcoming split into two separate companies. I am proud to see the impact our efforts are having on society and how we accomplish this each day."

    Financial Overview by Reporting Segment for the Third Quarter

    Discovery & Analytical Solutions Continuing Operations

    • Third quarter 2022 revenue was $313 million, as compared to $208 million in the same period a year ago. Reported revenue increased 51% and organic revenue increased 14% as compared to the same period a year ago.
    • Third quarter 2022 operating income from continuing operations was $33 million, as compared to $(19) million for the same period a year ago.
    • Third quarter 2022 adjusted operating income was $117 million, as compared to $58 million for the same period a year ago.

    Discovery & Analytical Solutions Pro Forma* Operations

    • Third quarter 2022 pro forma revenue was $633 million, as compared to $513 million in the same period a year ago. Pro forma revenue increased 23% and pro forma organic revenue increased 12% as compared to the same period a year ago.
    • Third quarter 2022 pro forma operating income was $58 million, as compared to $7 million for the same period a year ago.
    • Third quarter 2022 pro forma adjusted operating income was $165 million, as compared to $95 million for the same period a year ago.

    Diagnostics

    • Third quarter 2022 revenue was $399 million, as compared to $654 million for the same period a year ago. Reported revenue decreased 39% and organic revenue decreased 33% as compared to the same period a year ago.
    • Third quarter 2022 operating income from continuing operations was $95 million, as compared to $238 million for the same period a year ago.
    • Third quarter 2022 adjusted operating income was $123 million, as compared to $287 million for the same period a year ago.

    Initiates Fourth Quarter and Updates Full Year 2022 Guidance

    For the fourth quarter of 2022, the Company forecasts total revenue from continuing operations of $0.73 billion. Pro forma total revenue is expected to be in a range of approximately $1.06-$1.07 billion and pro forma adjusted earnings per share are expected to be in a range $1.65-$1.67.

    For the full year 2022, the Company now forecasts total revenue from continuing operations of $3.30 billion. Pro forma total revenue is expected to be in the range of approximately $4.59-$4.60 billion and pro forma adjusted earnings per share are expected to be in a range of $7.89-$7.91.

    The Company's guidance for the fourth quarter and full year with respect to non-GAAP metrics cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures. The timing and amounts of such events and items could be material to the Company's results prepared in accordance with GAAP.

    Webcast Information

    The Company will discuss its third quarter 2022 results and its outlook for business trends during a webcast on November 8, 2022, at 8:00 a.m. Eastern Time. A live audio webcast and presentation will be available on the Investors section of the Company's website, www.perkinelmer.com.

    Use of Non-GAAP Financial Measures

    In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings announcement also contains non-GAAP financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are included below following our GAAP financial statements.

    Factors Affecting Future Performance

    This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "estimates", "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) the effect of the COVID-19 pandemic on our sales and operations; (3) fluctuations in the global economic and political environments; (4) our failure to introduce new products in a timely manner; (5) our ability to execute acquisitions and divestitures, such as the divestiture of the Applied, Food and Enterprise Services businesses, license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (6) our ability to compete effectively; (7) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (8) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (9) disruptions in the supply of raw materials and supplies; (10) our ability to retain key personnel; (11) significant disruption in our information technology systems, or cybercrime; (12) our ability to realize the full value of our intangible assets; (13) our failure to adequately protect our intellectual property; (14) the loss of any of our licenses or licensed rights; (15) the manufacture and sale of products exposing us to product liability claims; (16) our failure to maintain compliance with applicable government regulations; (17) regulatory changes; (18) our failure to comply with healthcare industry regulations; (19) economic, political and other risks associated with foreign operations; (20) the United Kingdom's withdrawal from the European Union; (21) our ability to obtain future financing; (22) restrictions in our credit agreements; (23) discontinuation or replacement of LIBOR; (24) significant fluctuations in our stock price; (25) reduction or elimination of dividends on our common stock; and (26) other factors which we describe under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

    About PerkinElmer

    PerkinElmer is a leading, global provider of end-to-end solutions that help scientists, researchers and clinicians better diagnose disease, discover new and more personalized drugs, monitor the safety and quality of our food, and drive environmental and applied analysis excellence. With an 85-year legacy of advancing science and a mission of innovating for a healthier world, our dedicated team of more than 16,000 collaborates closely with commercial, government, academic and healthcare customers to deliver reagents, assays, instruments, automation, informatics and strategic services that accelerate workflows, deliver actionable insights and support improved decision making. We are also deeply committed to good corporate citizenship through our dynamic ESG and sustainability programs. The Company reported revenues of approximately $5 billion in 2021, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available at www.perkinelmer.com. Follow PerkinElmer on LinkedIn, Twitter, Facebook, Instagram, and YouTube.

      PerkinElmer, Inc. and Subsidiaries  
      CONDENSED CONSOLIDATED INCOME STATEMENTS  
               
       

    Three Months Ended

     

    Nine Months Ended

     
      (In thousands, except per share data)  

    October 2, 2022

     

    October 3, 2021

     

    October 2, 2022

     

    October 3, 2021

     
               
               
      Revenue  

    $

    711,803

     

     

    $

    861,316

     

     

    $

    2,570,608

     

     

    $

    2,799,898

     

     
               
      Cost of revenue  

     

    304,759

     

     

     

    338,454

     

     

     

    1,017,108

     

     

     

    1,009,707

     

     
      Selling, general and administrative expenses  

     

    239,969

     

     

     

    275,869

     

     

     

    765,746

     

     

     

    681,311

     

     
      Research and development expenses  

     

    53,521

     

     

     

    49,421

     

     

     

    167,081

     

     

     

    139,753

     

     
      Restructuring and other, net  

     

    2,774

     

     

     

    2,011

     

     

     

    15,443

     

     

     

    10,517

     

     
               
      Operating income from continuing operations  

     

    110,780

     

     

     

    195,561

     

     

     

    605,230

     

     

     

    958,610

     

     
               
      Interest income  

     

    (667

    )

     

     

    (544

    )

     

     

    (2,024

    )

     

     

    (1,322

    )

     
      Interest expense  

     

    25,931

     

     

     

    43,531

     

     

     

    81,447

     

     

     

    74,407

     

     
      Change in fair value of financial securities  

     

    5,106

     

     

     

    19,365

     

     

     

    14,321

     

     

     

    (8,566

    )

     
      Other (income) expense, net  

     

    (1,732

    )

     

     

    (1,803

    )

     

     

    (1,904

    )

     

     

    (9,787

    )

     
               
      Income from continuing operations, before income taxes  

     

    82,142

     

     

     

    135,012

     

     

     

    513,390

     

     

     

    903,878

     

     
               
      Provision for income taxes  

     

    12,634

     

     

     

    27,381

     

     

     

    98,211

     

     

     

    198,531

     

     
               
      Income from continuing operations  

     

    69,508

     

     

     

    107,631

     

     

     

    415,179

     

     

     

    705,347

     

     
               
      Income from discontinued operations, before income taxes  

     

    25,180

     

     

     

    26,656

     

     

     

    36,004

     

     

     

    64,329

     

     
      Provision for income taxes on discontinued operations and dispositions  

     

    9,341

     

     

     

    6,549

     

     

     

    9,662

     

     

     

    16,703

     

     
               
      Income from discontinued operations and dispositions  

     

    15,839

     

     

     

    20,107

     

     

     

    26,342

     

     

     

    47,626

     

     
               
      Net income  

    $

    85,347

     

     

    $

    127,738

     

     

    $

    441,521

     

     

    $

    752,973

     

     
               
               
      Diluted earnings per share:          
      Income from continuing operations  

    $

    0.55

     

     

    $

    0.94

     

     

    $

    3.28

     

     

    $

    6.23

     

     
               
      Income from discontinued operations and dispositions  

     

    0.13

     

     

     

    0.17

     

     

     

    0.21

     

     

     

    0.42

     

     
               
      Net income  

    $

    0.67

     

     

    $

    1.11

     

     

    $

    3.49

     

     

    $

    6.65

     

     
               
               
      Weighted average diluted shares of common stock outstanding  

     

    126,540

     

     

     

    115,022

     

     

     

    126,544

     

     

     

    113,307

     

     
               
      ABOVE PREPARED IN ACCORDANCE WITH GAAP  
               
      Additional Supplemental Information (1):          
      (per share, continuing operations)          
               
      GAAP EPS from continuing operations  

    $

    0.55

     

     

    $

    0.94

     

     

    $

    3.28

     

     

    $

    6.23

     

     
      Amortization of intangible assets  

     

    0.72

     

     

     

    0.55

     

     

     

    2.22

     

     

     

    1.40

     

     
      Gain from debt extinguishment  

     

    (0.00

    )

     

     

    -

     

     

     

    (0.00

    )

     

     

    -

     

     
      Purchase accounting adjustments  

     

    0.08

     

     

     

    0.09

     

     

     

    0.36

     

     

     

    0.17

     

     
      Acquisition and divestiture-related costs  

     

    0.07

     

     

     

    0.61

     

     

     

    0.20

     

     

     

    0.64

     

     
      Change in fair value of financial securities  

     

    0.04

     

     

     

    0.17

     

     

     

    0.11

     

     

     

    (0.08

    )

     
      Asset impairment  

     

    -

     

     

     

    0.03

     

     

     

    -

     

     

     

    0.03

     

     
      Significant litigation matters and settlements  

     

    0.00

     

     

     

    -

     

     

     

    (0.00

    )

     

     

    -

     

     
      Disposition of businesses and assets, net  

     

    -

     

     

     

    (0.02

    )

     

     

    -

     

     

     

    (0.02

    )

     
      Restructuring and other, net  

     

    0.02

     

     

     

    0.02

     

     

     

    0.12

     

     

     

    0.09

     

     
      Tax on above items  

     

    (0.24

    )

     

     

    (0.31

    )

     

     

    (0.77

    )

     

     

    (0.49

    )

     
      Significant tax items  

     

    (0.03

    )

     

     

    (0.01

    )

     

     

    (0.03

    )

     

     

    0.12

     

     
      Adjusted EPS from Continuing Operations  

    $

    1.21

     

     

    $

    2.07

     

     

    $

    5.50

     

     

    $

    8.10

     

     
               
      Adjusted EPS from AES  

    $

    0.30

     

     

    $

    0.24

     

     

    $

    0.75

     

     

    $

    0.74

     

     
               
      Pro Forma Adjusted EPS including the results of AES  

    $

    1.51

     

     

    $

    2.31

     

     

    $

    6.24

     

     

    $

    8.84

     

     
               
      (1) amounts may not sum due to rounding          
               
    PerkinElmer, Inc. and Subsidiaries
    REVENUE AND OPERATING INCOME (LOSS)
             
        Three Months Ended   Nine Months Ended
    (In thousands, except percentages)   October 2, 2022   October 3, 2021   October 2, 2022   October 3, 2021
               
               
    DAS   Reported revenue   $

    312,783

     

      $

    207,511

     

      $

    945,484

     

      $

    577,371

     

      Purchase accounting adjustments  

    -

     

     

    -

     

     

    -

     

     

    1,849

     

      Adjusted revenue  

    312,783

     

     

    207,511

     

     

    945,484

     

     

    579,220

     

               
      Reported operating income (loss) from continued operations

    32,631

     

     

    (19,263

    )

     

    106,005

     

     

    50,624

     

      OP%  

    10.4

    %

     

    -9.3

    %

     

    11.2

    %

     

    8.8

    %

      Amortization of intangible assets  

    64,426

     

     

    25,757

     

     

    185,094

     

     

    50,903

     

      Purchase accounting adjustments  

    9,164

     

     

    5,673

     

     

    43,710

     

     

    9,322

     

      Acquisition and divestiture-related costs  

    8,475

     

     

    44,409

     

     

    11,746

     

     

    46,498

     

      Significant litigation matters and settlements  

    629

     

     

    -

     

     

    (632

    )

     

    -

     

      Restructuring and other, net  

    1,556

     

     

    1,424

     

     

    11,738

     

     

    6,867

     

      Adjusted operating income  

    116,881

     

     

    58,000

     

     

    357,661

     

     

    164,214

     

      Adjusted OP%  

    37.4

    %

     

    28.0

    %

     

    37.8

    %

     

    28.4

    %

               
    Diagnostics   Reported revenue  

    399,020

     

     

    653,805

     

     

    1,625,124

     

     

    2,222,527

     

      Purchase accounting adjustments  

    203

     

     

    199

     

     

    609

     

     

    597

     

      Adjusted revenue  

    399,223

     

     

    654,004

     

     

    1,625,733

     

     

    2,223,124

     

               
      Reported operating income from continued operations  

    94,654

     

     

    237,903

     

     

    553,898

     

     

    965,650

     

      OP%  

    23.7

    %

     

    36.4

    %

     

    34.1

    %

     

    43.4

    %

      Amortization of intangible assets  

    27,099

     

     

    37,517

     

     

    95,375

     

     

    107,743

     

      Purchase accounting adjustments  

    457

     

     

    5,107

     

     

    1,884

     

     

    9,485

     

      Asset impairment  

    -

     

     

    3,868

     

     

    -

     

     

    3,868

     

      Acquisition and divestiture-related costs  

    -

     

     

    2,023

     

     

    14,119

     

     

    7,833

     

      Restructuring and other, net  

    1,218

     

     

    587

     

     

    3,705

     

     

    3,650

     

      Adjusted operating income  

    123,428

     

     

    287,005

     

     

    668,981

     

     

    1,098,229

     

      Adjusted OP%  

    30.9

    %

     

    43.9

    %

     

    41.1

    %

     

    49.4

    %

               
    Corporate   Reported operating loss  

    (16,505

    )

     

    (23,079

    )

     

    (54,673

    )

     

    (57,664

    )

               
    Continuing Operations   Reported revenue   $

    711,803

     

      $

    861,316

     

      $

    2,570,608

     

      $

    2,799,898

     

      Purchase accounting adjustments  

    203

     

     

    199

     

     

    609

     

     

    2,446

     

      Adjusted revenue  

    712,006

     

     

    861,515

     

     

    2,571,217

     

     

    2,802,344

     

               
      Reported operating income from continued operations  

    110,780

     

     

    195,561

     

     

    605,230

     

     

    958,610

     

      OP%  

    15.6

    %

     

    22.7

    %

     

    23.5

    %

     

    34.2

    %

      Amortization of intangible assets  

    91,525

     

     

    63,274

     

     

    280,469

     

     

    158,646

     

      Purchase accounting adjustments  

    9,621

     

     

    10,780

     

     

    45,594

     

     

    18,807

     

      Acquisition and divestiture-related costs  

    8,475

     

     

    46,432

     

     

    25,865

     

     

    54,331

     

      Asset impairment  

    -

     

     

    3,868

     

     

    -

     

     

    3,868

     

      Significant litigation matters and settlements  

    629

     

     

    -

     

     

    (632

    )

     

    -

     

      Restructuring and other, net  

    2,774

     

     

    2,011

     

     

    15,443

     

     

    10,517

     

      Adjusted operating income   $

    223,804

     

      $

    321,926

     

      $

    971,969

     

      $

    1,204,779

     

      Adjusted OP%  

    31.4

    %

     

    37.4

    %

     

    37.8

    %

     

    43.0

    %

               
    REPORTED REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP
    PerkinElmer, Inc. and Subsidiaries
    RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)
             
      Three Months Ended   Nine Months Ended
    (In thousands, except percentages)   October 2, 2022   October 3, 2021   October 2, 2022   October 3, 2021
             
             
    DAS Reported revenue   $

    312,783

     

      $

    207,511

     

      $

    945,484

     

      $

    577,371

     

    Purchase accounting adjustments  

    -

     

     

    -

     

     

    -

     

     

    1,849

     

    Adjusted revenue  

    312,783

     

     

    207,511

     

     

    945,484

     

     

    579,220

     

             
    Reported operating income from continued operations  

    32,631

     

     

    (19,263

    )

     

    106,005

     

     

    50,624

     

    OP%  

    10.4

    %

     

    -9.3

    %

     

    11.2

    %

     

    8.8

    %

    Amortization of intangible assets  

    64,426

     

     

    25,757

     

     

    185,094

     

     

    50,903

     

    Purchase accounting adjustments  

    9,164

     

     

    5,673

     

     

    43,710

     

     

    9,322

     

    Acquisition and divestiture-related costs  

    8,475

     

     

    44,409

     

     

    11,746

     

     

    46,498

     

    Significant litigation matters and settlements  

    629

     

     

    -

     

     

    (632

    )

     

    -

     

    Restructuring and other, net  

    1,556

     

     

    1,424

     

     

    11,738

     

     

    6,867

     

    Adjusted operating income  

    116,881

     

     

    58,000

     

     

    357,661

     

     

    164,214

     

    Adjusted OP%  

    37.4

    %

     

    28.0

    %

     

    37.8

    %

     

    28.4

    %

             
    AES Discontinued Operations Revenue in Discontinued Ops  

    320,616

     

     

    305,369

     

     

    950,822

     

     

    902,946

     

             
    Reported operating income in discontinued operations  

    25,389

     

     

    26,409

     

     

    36,642

     

     

    63,624

     

    OP%  

    7.9

    %

     

    8.6

    %

     

    3.9

    %

     

    7.0

    %

    Amortization of intangible assets  

    2,387

     

     

    7,680

     

     

    16,984

     

     

    26,026

     

    Acquisition and divestiture-related costs  

    22,026

     

     

    2,651

     

     

    47,042

     

     

    15,066

     

    Restructuring and other, net  

    486

     

     

    200

     

     

    13,131

     

     

    2,501

     

    Pro-Forma deprecation on assets held for sale  

    (2,363

    )

     

    -

     

     

    (2,363

    )

     

    -

     

    Adjusted operating income of AES  

    47,925

     

     

    36,940

     

     

    111,436

     

     

    107,217

     

    Adjusted OP%  

    14.9

    %

     

    12.1

    %

     

    11.7

    %

     

    11.9

    %

             
    Pro Forma DAS Revenue including AES  

    633,399

     

     

    512,880

     

     

    1,896,306

     

     

    1,480,317

     

    Purchase accounting adjustments  

    -

     

     

    -

     

     

    -

     

     

    1,849

     

    Adjusted revenue including AES  

    633,399

     

     

    512,880

     

     

    1,896,306

     

     

    1,482,166

     

             
    Operating income including AES  

    58,020

     

     

    7,146

     

     

    142,647

     

     

    114,248

     

    OP%  

    9.2

    %

     

    1.4

    %

     

    7.5

    %

     

    7.7

    %

    Amortization of intangible assets  

    66,813

     

     

    33,437

     

     

    202,078

     

     

    76,929

     

    Purchase accounting adjustments  

    9,164

     

     

    5,673

     

     

    43,710

     

     

    9,322

     

    Acquisition and divestiture-related costs  

    30,501

     

     

    47,060

     

     

    58,788

     

     

    61,564

     

    Significant litigation matters and settlements  

    629

     

     

    -

     

     

    (632

    )

     

    -

     

    Restructuring and other, net  

    2,042

     

     

    1,624

     

     

    24,869

     

     

    9,368

     

    Pro-Forma deprecation on assets held for sale  

    (2,363

    )

     

    -

     

     

    (2,363

    )

     

    -

     

    Adjusted operating income including AES  

    164,806

     

     

    94,940

     

     

    469,097

     

     

    271,431

     

    Adjusted OP%  

    26.0

    %

     

    18.5

    %

     

    24.7

    %

     

    18.3

    %

             
    Diagnostics Reported revenue  

    399,020

     

     

    653,805

     

     

    1,625,124

     

     

    2,222,527

     

    Purchase accounting adjustments  

    203

     

     

    199

     

     

    609

     

     

    597

     

    Adjusted revenue  

    399,223

     

     

    654,004

     

     

    1,625,733

     

     

    2,223,124

     

             
    Reported operating income from continued operations  

    94,654

     

     

    237,903

     

     

    553,898

     

     

    965,650

     

    OP%  

    23.7

    %

     

    36.4

    %

     

    34.1

    %

     

    43.4

    %

    Amortization of intangible assets  

    27,099

     

     

    37,517

     

     

    95,375

     

     

    107,743

     

    Purchase accounting adjustments  

    457

     

     

    5,107

     

     

    1,884

     

     

    9,485

     

    Asset impairment  

    -

     

     

    3,868

     

     

    -

     

     

    3,868

     

    Acquisition and divestiture-related costs  

    -

     

     

    2,023

     

     

    14,119

     

     

    7,833

     

    Restructuring and other, net  

    1,218

     

     

    587

     

     

    3,705

     

     

    3,650

     

    Adjusted operating income  

    123,428

     

     

    287,005

     

     

    668,981

     

     

    1,098,229

     

    Adjusted OP%  

    30.9

    %

     

    43.9

    %

     

    41.1

    %

     

    49.4

    %

             
    Corporate Reported operating loss  

    (16,505

    )

     

    (23,079

    )

     

    (54,673

    )

     

    (57,664

    )

             
    Pro Forma Operating Results including AES Revenue including AES   $

    1,032,419

     

      $

    1,166,685

     

      $

    3,521,430

     

      $

    3,702,844

     

    Purchase accounting adjustments  

    203

     

     

    199

     

     

    609

     

     

    2,446

     

    Adjusted revenue including AES  

    1,032,622

     

     

    1,166,884

     

     

    3,522,039

     

     

    3,705,290

     

             
    Operating income including AES  

    136,169

     

     

    221,970

     

     

    641,872

     

     

    1,022,234

     

    OP%  

    13.2

    %

     

    19.0

    %

     

    18.2

    %

     

    27.6

    %

    Amortization of intangible assets  

    93,912

     

     

    70,954

     

     

    297,453

     

     

    184,672

     

    Purchase accounting adjustments  

    9,621

     

     

    10,780

     

     

    45,594

     

     

    18,807

     

    Acquisition and divestiture-related costs  

    30,501

     

     

    49,083

     

     

    72,907

     

     

    69,397

     

    Asset impairment  

    -

     

     

    3,868

     

     

    -

     

     

    3,868

     

    Significant litigation matters and settlements  

    629

     

     

    -

     

     

    (632

    )

     

    -

     

    Restructuring and other, net  

    3,260

     

     

    2,211

     

     

    28,574

     

     

    13,018

     

    Pro-Forma deprecation on assets held for sale  

    (2,363

    )

     

    -

     

     

    (2,363

    )

     

    -

     

    Adjusted operating income including AES   $

    271,729

     

      $

    358,866

     

      $

    1,083,405

     

      $

    1,311,996

     

    Adjusted OP%  

    26.3

    %

     

    30.8

    %

     

    30.8

    %

     

    35.4

    %

             
    REPORTED REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP
             
    (1) amounts may not sum due to rounding
    PerkinElmer, Inc. and Subsidiaries
    CONDENSED CONSOLIDATED BALANCE SHEETS
         
    (In thousands)   October 2, 2022   January 2, 2022
         
    Current assets:    
    Cash and cash equivalents  

    $

    400,741

     

    $

    603,320

    Accounts receivable, net  

     

    540,867

     

     

    707,941

    Inventories, net  

     

    378,256

     

     

    425,890

    Other current assets  

     

    138,867

     

     

    148,255

    Current assets of discontinued operations  

     

    1,657,749

     

     

    555,374

    Total current assets  

     

    3,116,480

     

     

    2,440,780

         
    Property, plant and equipment, net  

     

    460,397

     

     

    485,531

    Operating lease right-of-use assets  

     

    160,120

     

     

    164,040

    Intangible assets, net  

     

    3,401,143

     

     

    3,821,847

    Goodwill  

     

    6,373,327

     

     

    6,627,119

    Other assets, net  

     

    312,297

     

     

    312,887

    Long-term assets of discontinued operations  

     

    -

     

     

    1,148,350

    Total assets  

    $

    13,823,764

     

    $

    15,000,554

         
    Current liabilities:    
    Current portion of long-term debt  

    $

    503,549

     

    $

    4,240

    Accounts payable  

     

    275,824

     

     

    324,811

    Accrued expenses and other current liabilities  

     

    471,570

     

     

    728,445

    Current liabilities of discontinued operations  

     

    234,788

     

     

    156,248

    Total current liabilities  

     

    1,485,731

     

     

    1,213,744

         
    Long-term debt  

     

    3,898,267

     

     

    4,979,737

    Long-term liabilities  

     

    1,231,724

     

     

    1,413,196

    Operating lease liabilities  

     

    142,842

     

     

    147,395

    Long-term liabilities of discontinued operations  

     

    -

     

     

    105,237

    Total liabilities  

     

    6,758,564

     

     

    7,859,309

         
    Total stockholders' equity  

     

    7,065,200

     

     

    7,141,245

    Total liabilities and stockholders' equity  

    $

    13,823,764

     

    $

    15,000,554

         
         
    PREPARED IN ACCORDANCE WITH GAAP
    PerkinElmer, Inc. and Subsidiaries
    CONSOLIDATED STATEMENTS OF CASH FLOWS
         
             
      Three Months Ended   Nine Months Ended
      October 2, 2022   October 3, 2021   October 2, 2022   October 3, 2021
      (In thousands)   (In thousands)
             
    Operating activities:        
    Net income  

    $

    85,347

     

     

    $

    127,738

     

     

    $

    441,521

     

     

    $

    752,973

     

    Income from discontinued operations and dispositions, net of income taxes  

     

    (15,839

    )

     

     

    (20,107

    )

     

     

    (26,342

    )

     

     

    (47,626

    )

    Income from continuing operations  

     

    69,508

     

     

     

    107,631

     

     

     

    415,179

     

     

     

    705,347

     

    Adjustments to reconcile income from continuing operations to net cash provided by continuing operations:        
    Stock-based compensation  

     

    10,112

     

     

     

    5,835

     

     

     

    39,776

     

     

     

    16,718

     

    Restructuring and other, net  

     

    2,774

     

     

     

    2,011

     

     

     

    15,443

     

     

     

    10,517

     

    Depreciation and amortization  

     

    104,736

     

     

     

    76,146

     

     

     

    322,766

     

     

     

    197,386

     

    Change in fair value of contingent consideration  

     

    (2,132

    )

     

     

    1,076

     

     

     

    (769

    )

     

     

    1,553

     

    Amortization of deferred debt financing costs and accretion of discounts  

     

    2,194

     

     

     

    1,500

     

     

     

    6,046

     

     

     

    3,224

     

    Change in fair value of financial securities  

     

    5,106

     

     

     

    19,365

     

     

     

    14,321

     

     

     

    (8,566

    )

    Debt extinguishment income  

     

    (580

    )

     

     

    -

     

     

     

    (92

    )

     

     

    -

     

    Amortization of acquired inventory revaluation  

     

    11,315

     

     

     

    9,425

     

     

     

    45,039

     

     

     

    14,728

     

    Gain on disposition of businesses and assets, net  

     

    -

     

     

     

    (1,970

    )

     

     

    -

     

     

     

    (1,970

    )

    Asset impairment  

     

    -

     

     

     

    3,868

     

     

     

    -

     

     

     

    3,868

     

    Changes in assets and liabilities which provided (used) cash, excluding effects from companies acquired:        
    Accounts receivable, net  

     

    28,637

     

     

     

    87,718

     

     

     

    93,092

     

     

     

    224,162

     

    Inventories  

     

    (19,996

    )

     

     

    7,796

     

     

     

    (61,632

    )

     

     

    14,683

     

    Accounts payable  

     

    (16,429

    )

     

     

    (9,358

    )

     

     

    (24,314

    )

     

     

    (40,009

    )

    Accrued expenses and other  

     

    (72,496

    )

     

     

    (20,787

    )

     

     

    (338,223

    )

     

     

    (168,949

    )

    Net cash provided by operating activities of continuing operations  

     

    122,749

     

     

     

    290,256

     

     

     

    526,632

     

     

     

    972,692

     

    Net cash provided by operating activities of discontinued operations  

     

    37,205

     

     

     

    23,539

     

     

     

    14,020

     

     

     

    102,466

     

    Net cash provided by operating activities  

     

    159,954

     

     

     

    313,795

     

     

     

    540,652

     

     

     

    1,075,158

     

             
    Investing activities:        
    Capital expenditures  

     

    (13,095

    )

     

     

    (26,365

    )

     

     

    (59,502

    )

     

     

    (59,066

    )

    Purchases of investments  

     

    (17,765

    )

     

     

    (4,623

    )

     

     

    (45,010

    )

     

     

    (19,130

    )

    Proceeds from notes receivables  

     

    8,890

     

     

     

    -

     

     

     

    8,890

     

     

     

    -

     

    Proceeds from disposition of businesses and assets  

     

    4,610

     

     

     

    1,460

     

     

     

    5,664

     

     

     

    1,460

     

    Cash paid for acquisitions, net of cash acquired  

     

    (1,884

    )

     

     

    (3,264,981

    )

     

     

    (7,768

    )

     

     

    (3,967,678

    )

    Net cash used in investing activities of continuing operations  

     

    (19,244

    )

     

     

    (3,294,509

    )

     

     

    (97,726

    )

     

     

    (4,044,414

    )

    Net cash used in investing activities of discontinued operations  

     

    (3,263

    )

     

     

    (6,419

    )

     

     

    (9,441

    )

     

     

    (8,393

    )

    Net cash used in investing activities  

     

    (22,507

    )

     

     

    (3,300,928

    )

     

     

    (107,167

    )

     

     

    (4,052,807

    )

             
    Financing Activities:        
    Payments on borrowings  

     

    -

     

     

     

    (427,580

    )

     

     

    (220,000

    )

     

     

    (1,191,125

    )

    Proceeds from borrowings  

     

    -

     

     

     

    415,282

     

     

     

    220,000

     

     

     

    1,144,282

     

    Payments of term loan  

     

    (50,000

    )

     

     

    -

     

     

     

    (500,000

    )

     

     

    -

     

    Proceeds from term loan  

     

    -

     

     

     

    500,000

     

     

     

    -

     

     

     

    500,000

     

    Payments of senior debt  

     

    (7,472

    )

     

     

    -

     

     

     

    (7,472

    )

     

     

    (339,605

    )

    Proceeds from sale of senior debt  

     

    -

     

     

     

    2,286,239

     

     

     

    -

     

     

     

    3,086,095

     

    Payments of debt financing costs  

     

    -

     

     

     

    (22,741

    )

     

     

    -

     

     

     

    (30,983

    )

    Settlement of cash flow hedges  

     

    -

     

     

     

    4,477

     

     

     

    (762

    )

     

     

    (1,459

    )

    Net payments on other credit facilities  

     

    343

     

     

     

    (905

    )

     

     

    (487

    )

     

     

    (12,731

    )

    Proceeds from issuance of common stock under stock plans  

     

    413

     

     

     

    8,575

     

     

     

    6,254

     

     

     

    22,760

     

    Purchases of common stock  

     

    (89

    )

     

     

    (89

    )

     

     

    (56,137

    )

     

     

    (73,013

    )

    Dividends paid  

     

    (8,835

    )

     

     

    (7,842

    )

     

     

    (26,502

    )

     

     

    (23,539

    )

    Net cash (used in) provided by financing activities of continuing operations  

     

    (65,640

    )

     

     

    2,755,416

     

     

     

    (585,106

    )

     

     

    3,080,682

     

    Net cash (used in) provided by financing activities of discontinued operations  

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

    Net cash (used in) provided by financing activities  

     

    (65,640

    )

     

     

    2,755,416

     

     

     

    (585,106

    )

     

     

    3,080,682

     

             
    Effect of exchange rate changes on cash, cash equivalents, and restricted cash  

     

    (17,427

    )

     

     

    (5,925

    )

     

     

    (51,404

    )

     

     

    (16,584

    )

             
    Net increase (decrease) in cash, cash equivalents, and restricted cash  

     

    54,380

     

     

     

    (237,642

    )

     

     

    (203,025

    )

     

     

    86,449

     

    Cash, cash equivalents, and restricted cash at beginning of period  

     

    361,932

     

     

     

    726,704

     

     

     

    619,337

     

     

     

    402,613

     

    Cash, cash equivalents, and restricted cash at end of period  

    $

    416,312

     

     

    $

    489,062

     

     

    $

    416,312

     

     

    $

    489,062

     

             
             
    Supplemental disclosure of cash flow information:        
    Reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total shown in the consolidated statements of cash flows:        
    Cash and cash equivalents  

    $

    400,741

     

     

    $

    472,374

     

     

    $

    400,741

     

     

    $

    472,374

     

    Restricted cash included in other current assets  

     

    284

     

     

     

    1,689

     

     

     

    284

     

     

     

    1,689

     

    Restricted cash included in other assets  

     

    288

     

     

     

    -

     

     

     

    288

     

     

     

    -

     

    Cash and cash equivalents included in current assets of discontinued operations  

     

    14,999

     

     

     

    14,999

     

     

     

    14,999

     

     

     

    14,999

     

    Total cash, cash equivalents and restricted cash  

    $

    416,312

     

     

    $

    489,062

     

     

    $

    416,312

     

     

    $

    489,062

     

             
    PREPARED IN ACCORDANCE WITH GAAP
    PerkinElmer, Inc. and Subsidiaries
    RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)
             
    (In millions, except per share data and percentages)   PKI
     

    Three Months Ended

     

    October 2, 2022

       

    October 3, 2021

     
    Adjusted revenue:        
    Revenue  

    $

    711.8

     

       

    $

    861.3

     

     
    Purchase accounting adjustments  

     

    0.2

     

       

     

    0.2

     

     
    Adjusted revenue  

    $

    712.0

     

       

    $

    861.5

     

     
             
    Adjusted gross margin:        
    Gross margin  

    $

    407.0

     

     

    57.2

    %

     

    $

    522.9

     

     

    60.7

    %

    Amortization of intangible assets  

     

    35.3

     

     

    5.0

    %

     

     

    28.5

     

     

    3.3

    %

    Purchase accounting adjustments  

     

    11.7

     

     

    1.6

    %

     

     

    9.6

     

     

    1.1

    %

    Acquisition and divestiture-related costs  

     

    1.5

     

     

    0.2

    %

     

     

    -

     

     

    0.0

    %

    Adjusted gross margin  

    $

    455.5

     

     

    64.0

    %

     

    $

    560.9

     

     

    65.1

    %

         
    Adjusted SG&A:        
    SG&A  

    $

    240.0

     

     

    33.7

    %

     

    $

    275.9

     

     

    32.0

    %

    Amortization of intangible assets  

     

    (56.2

    )

     

    -7.9

    %

     

     

    (34.8

    )

     

    -4.0

    %

    Purchase accounting adjustments  

     

    2.1

     

     

    0.3

    %

     

     

    (1.2

    )

     

    -0.1

    %

    Acquisition and divestiture-related costs  

     

    (5.7

    )

     

    -0.8

    %

     

     

    (46.4

    )

     

    -5.4

    %

    Asset impairment  

     

    -

     

     

    0.0

    %

     

     

    (3.9

    )

     

    -0.4

    %

    Significant litigation matters and settlements  

     

    (0.6

    )

     

    -0.1

    %

     

     

    -

     

     

    0.0

    %

    Adjusted SG&A  

    $

    179.6

     

     

    25.2

    %

     

    $

    189.6

     

     

    22.0

    %

             
    Adjusted R&D:        
    R&D  

    $

    53.5

     

     

    7.5

    %

     

    $

    49.4

     

     

    5.7

    %

    Purchase accounting adjustments  

     

    (0.1

    )

     

    0.0

    %

     

     

    -

     

     

    0.0

    %

    Acquisition and divestiture-related costs  

     

    (1.3

    )

     

    -0.2

    %

     

     

    -

     

     

    0.0

    %

    Adjusted R&D  

    $

    52.2

     

     

    7.3

    %

     

    $

    49.4

     

     

    5.7

    %

             
    Adjusted operating income:        
    Operating income  

    $

    110.8

     

     

    15.6

    %

     

    $

    195.6

     

     

    22.7

    %

    Amortization of intangible assets  

     

    91.5

     

     

    12.9

    %

     

     

    63.3

     

     

    7.3

    %

    Purchase accounting adjustments  

     

    9.6

     

     

    1.4

    %

     

     

    10.8

     

     

    1.3

    %

    Acquisition and divestiture-related costs  

     

    8.5

     

     

    1.2

    %

     

     

    46.4

     

     

    5.4

    %

    Asset impairment  

     

    -

     

     

    0.0

    %

     

     

    3.9

     

     

    0.4

    %

    Significant litigation matters and settlements  

     

    0.6

     

     

    0.1

    %

     

     

    -

     

     

    0.0

    %

    Restructuring and other, net  

     

    2.8

     

     

    0.4

    %

     

     

    2.0

     

     

    0.2

    %

    Adjusted operating income  

    $

    223.8

     

     

    31.4

    %

     

    $

    321.9

     

     

    37.4

    %

             
      PKI
     

    Three Months Ended

     

    October 2, 2022

       

    October 3, 2021

     
    Adjusted EPS:        
    GAAP EPS  

    $

    0.67

     

       

    $

    1.11

     

     
    Discontinued operations, net of income taxes  

     

    0.13

     

       

     

    0.17

     

     
    GAAP EPS from continuing operations  

     

    0.55

     

       

     

    0.94

     

     
    Amortization of intangible assets  

     

    0.72

     

       

     

    0.55

     

     
    Debt extinguishment costs  

     

    (0.00

    )

       

     

    -

     

     
    Purchase accounting adjustments  

     

    0.08

     

       

     

    0.09

     

     
    Acquisition and divestiture-related costs  

     

    0.07

     

       

     

    0.61

     

     
    Change in fair value of financial securities  

     

    0.04

     

       

     

    0.17

     

     
    Asset impairment  

     

    -

     

       

     

    0.03

     

     
    Significant litigation matters and settlements  

     

    0.00

     

       

     

    -

     

     
    Disposition of businesses and assets, net  

     

    -

     

       

     

    (0.02

    )

     
    Restructuring and other, net  

     

    0.02

     

       

     

    0.02

     

     
    Tax on above items  

     

    (0.24

    )

       

     

    (0.31

    )

     
    Significant tax items  

     

    (0.03

    )

       

     

    (0.01

    )

     
    Adjusted EPS  

    $

    1.21

     

       

    $

    2.07

     

     
             
    GAAP EPS from discontinued operations  

     

    0.13

     

       

     

    0.17

     

     
    Amortization of intangible assets included in discontinued operations  

     

    0.02

     

       

     

    0.07

     

     
    Acquisition and divestiture-related costs included in discontinued operations  

     

    0.17

     

       

     

    0.02

     

     
    Restructuring and other, net included in discontinued operations  

     

    0.00

     

       

     

    0.00

     

     
    Pro Forma depreciation expense on assets held for sale  

     

    (0.02

    )

       

     

    -

     

     
    Tax on above items  

     

    (0.00

    )

       

     

    (0.02

    )

     
    Less non-AES income tax items in discontinued operations  

     

    0.00

     

       

     

    0.00

     

     
    Adjusted EPS from AES  

    $

    0.30

     

       

    $

    0.24

     

     
             
    Pro Forma Adjusted EPS including the results of AES  

    $

    1.51

     

       

    $

    2.31

     

     
             
      DAS
     

    Three Months Ended

     

    October 2, 2022

       

    October 3, 2021

     
             
    Revenue  

    $

    312.8

     

       

    $

    207.5

     

     
             
    Adjusted operating income:        
    Operating income  

    $

    32.6

     

     

    10.4

    %

     

    $

    (19.3

    )

     

    -9.3

    %

    Amortization of intangible assets  

     

    64.4

     

     

    20.6

    %

     

     

    25.8

     

     

    12.4

    %

    Purchase accounting adjustments  

     

    9.2

     

     

    2.9

    %

     

     

    5.7

     

     

    2.7

    %

    Acquisition and divestiture-related costs  

     

    8.5

     

     

    2.7

    %

     

     

    44.4

     

     

    21.4

    %

    Significant litigation matters and settlements  

     

    0.6

     

     

    0.2

    %

     

     

    -

     

     

    0.0

    %

    Restructuring and other, net  

     

    1.6

     

     

    0.5

    %

     

     

    1.4

     

     

    0.7

    %

    Adjusted operating income  

    $

    116.9

     

     

    37.4

    %

     

    $

    58.0

     

     

    28.0

    %

             
      Diagnostics
     

    Three Months Ended

     

    October 2, 2022

       

    October 3, 2021

     
    Adjusted revenue:        
    Revenue  

    $

    399.0

     

       

    $

    653.8

     

     
    Purchase accounting adjustments  

     

    0.2

     

       

     

    0.2

     

     
    Adjusted revenue  

    $

    399.2

     

       

    $

    654.0

     

     
             
    Adjusted operating income:        
    Operating income  

    $

    94.7

     

     

    23.7

    %

     

    $

    237.9

     

     

    36.4

    %

    Amortization of intangible assets  

     

    27.1

     

     

    6.8

    %

     

     

    37.5

     

     

    5.7

    %

    Purchase accounting adjustments  

     

    0.5

     

     

    0.1

    %

     

     

    5.1

     

     

    0.8

    %

    Asset impairment  

     

    -

     

     

    0.0

    %

     

     

    3.9

     

     

    0.6

    %

    Acquisition and divestiture-related costs  

     

    -

     

     

    0.0

    %

     

     

    2.0

     

     

    0.3

    %

    Restructuring and other, net  

     

    1.2

     

     

    0.3

    %

     

     

    0.6

     

     

    0.1

    %

    Adjusted operating income  

    $

    123.4

     

     

    30.9

    %

     

    $

    287.0

     

     

    43.9

    %

             
    (1) amounts may not sum due to rounding        
    PerkinElmer, Inc. and Subsidiaries
    RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)
             
    (In millions, except per share data and percentages)   PKI
     

    Nine Months Ended

      October 2, 2022     October 3, 2021  
    Adjusted revenue:        
    Revenue  

    $

    2,570.6

     

       

    $

    2,799.9

     

     
    Purchase accounting adjustments  

     

    0.6

     

       

     

    2.4

     

     
    Adjusted revenue  

    $

    2,571.2

     

       

    $

    2,802.3

     

     
             
    Adjusted gross margin:        
    Gross margin  

    $

    1,553.5

     

     

    60.4

    %

     

    $

    1,790.2

     

     

    63.9

    %

    Amortization of intangible assets  

     

    107.1

     

     

    4.2

    %

     

     

    64.3

     

     

    2.3

    %

    Purchase accounting adjustments  

     

    46.1

     

     

    1.8

    %

     

     

    17.2

     

     

    0.6

    %

    Acquisition and divestiture-related costs  

     

    4.7

     

     

    0.2

    %

     

     

    -

     

     

    0.0

    %

    Adjusted gross margin  

    $

    1,711.3

     

     

    66.6

    %

     

    $

    1,871.7

     

     

    66.8

    %

         
    Adjusted SG&A:        
    SG&A  

    $

    765.7

     

     

    29.8

    %

     

    $

    681.3

     

     

    24.3

    %

    Amortization of intangible assets  

     

    (173.4

    )

     

    -6.7

    %

     

     

    (94.3

    )

     

    -3.4

    %

    Purchase accounting adjustments  

     

    0.6

     

     

    0.0

    %

     

     

    (1.6

    )

     

    -0.1

    %

    Acquisition and divestiture-related costs  

     

    (17.1

    )

     

    -0.7

    %

     

     

    (54.3

    )

     

    -1.9

    %

    Asset impairment  

     

    -

     

     

    0.0

    %

     

     

    (3.9

    )

     

    -0.1

    %

    Significant litigation matters and settlements  

     

    0.6

     

     

    0.0

    %

     

     

    -

     

     

    0.0

    %

    Adjusted SG&A  

    $

    576.5

     

     

    22.4

    %

     

    $

    527.1

     

     

    18.8

    %

             
    Adjusted R&D:        
    R&D  

    $

    167.1

     

     

    6.5

    %

     

    $

    139.8

     

     

    5.0

    %

    Purchase accounting adjustments  

     

    (0.2

    )

     

    0.0

    %

     

     

    -

     

     

    0.0

    %

    Acquisition and divestiture-related costs  

     

    (4.1

    )

     

    -0.2

    %

     

     

    -

     

     

    0.0

    %

    Adjusted R&D  

    $

    162.8

     

     

    6.3

    %

     

    $

    139.8

     

     

    5.0

    %

             
    Adjusted operating income:        
    Operating income  

    $

    605.2

     

     

    23.5

    %

     

    $

    958.6

     

     

    34.2

    %

    Amortization of intangible assets  

     

    280.5

     

     

    10.9

    %

     

     

    158.6

     

     

    5.7

    %

    Purchase accounting adjustments  

     

    45.6

     

     

    1.8

    %

     

     

    18.8

     

     

    0.7

    %

    Acquisition and divestiture-related costs  

     

    25.9

     

     

    1.0

    %

     

     

    54.3

     

     

    1.9

    %

    Asset impairment  

     

    -

     

     

    0.0

    %

     

     

    3.9

     

     

    0.1

    %

    Significant litigation matters and settlements  

     

    (0.6

    )

     

    0.0

    %

     

     

    -

     

     

    0.0

    %

    Restructuring and other, net  

     

    15.4

     

     

    0.6

    %

     

     

    10.5

     

     

    0.4

    %

    Adjusted operating income  

    $

    972.0

     

     

    37.8

    %

     

    $

    1,204.8

     

     

    43.0

    %

             
      PKI
     

    Nine Months Ended

      October 2, 2022     October 3, 2021  
    Adjusted EPS:        
    GAAP EPS  

    $

    3.49

     

       

    $

    6.65

     

     
    Discontinued operations  

     

    0.21

     

       

     

    0.42

     

     
    GAAP EPS from continuing operations  

     

    3.28

     

       

     

    6.23

     

     
    Amortization of intangible assets  

     

    2.22

     

       

     

    1.40

     

     
    Debt extinguishment costs  

     

    (0.00

    )

       

     

    -

     

     
    Purchase accounting adjustments  

     

    0.36

     

       

     

    0.17

     

     
    Acquisition and divestiture-related costs  

     

    0.20

     

       

     

    0.64

     

     
    Change in fair value of financial securities  

     

    0.11

     

       

     

    (0.08

    )

     
    Asset impairment  

     

    -

     

       

     

    0.03

     

     
    Significant litigation matters and settlements  

     

    (0.00

    )

       

     

    -

     

     
    Disposition of businesses and assets, net  

     

    -

     

       

     

    (0.02

    )

     
    Restructuring and other, net  

     

    0.12

     

       

     

    0.09

     

     
    Tax on above items  

     

    (0.77

    )

       

     

    (0.49

    )

     
    Significant tax items  

     

    (0.03

    )

       

     

    0.12

     

     
    Adjusted EPS  

    $

    5.50

     

       

    $

    8.10

     

     
             
    GAAP EPS from discontinued operations  

     

    0.21

     

       

     

    0.42

     

     
    Amortization of intangible assets included in discontinued operations  

     

    0.13

     

       

     

    0.23

     

     
    Acquisition and divestiture-related costs included in discontinued operations  

     

    0.37

     

       

     

    0.13

     

     
    Restructuring and other, net included in discontinued operations  

     

    0.10

     

       

     

    0.02

     

     
    Pro Forma depreciation expense on assets held for sale  

     

    (0.02

    )

       

     

    -

     

     
    Tax on above items  

     

    (0.05

    )

       

     

    (0.06

    )

     
    Less non-AES income tax items in discontinued operations  

     

    0.00

     

       

     

    0.00

     

     
    Adjusted EPS from AES  

    $

    0.75

     

       

    $

    0.74

     

     
             
    Pro forma adjusted EPS including the results of AES  

    $

    6.24

     

       

    $

    8.84

     

     
             
      PKI
     

    Three Months Ended

     

     

     

    Twelve Months Ended

     
     

    January 1, 2023

     

     

     

    January 1, 2023

     
    Pro forma adjusted revenue:  

    Projected

     

     

     

    Projected

     
    GAAP revenue from continuing operations  

    $

    730

       

    $

    3,300

     
    AES revenue  

     

    330 - 340

       

    1,290 - 1,300

     
    Pro forma adjusted revenue  

    $1,060 - $1,070

       

    $4,590 $4,600

     
             
      DAS
     

    Nine Months Ended

      October 2, 2022     October 3, 2021  
             
    Revenue  

    $

    945.5

     

       

    $

    577.4

     

     
             
    Adjusted operating income:        
    Operating income  

    $

    106.0

     

     

    11.2

    %

     

    $

    50.6

     

     

    8.8

    %

    Amortization of intangible assets  

     

    185.1

     

     

    19.6

    %

     

     

    50.9

     

     

    8.8

    %

    Purchase accounting adjustments  

     

    43.7

     

     

    4.6

    %

     

     

    9.3

     

     

    1.6

    %

    Acquisition and divestiture-related costs  

     

    11.7

     

     

    1.2

    %

     

     

    46.5

     

     

    8.1

    %

    Significant litigation matters and settlements  

     

    (0.6

    )

     

    -0.1

    %

     

     

    -

     

     

    0.0

    %

    Restructuring and other, net  

     

    11.7

     

     

    1.2

    %

     

     

    6.9

     

     

    1.2

    %

    Adjusted operating income  

    $

    357.7

     

     

    37.8

    %

     

    $

    164.2

     

     

    28.4

    %

             
      Diagnostics
     

    Nine Months Ended

      October 2, 2022     October 3, 2021  
    Adjusted revenue:        
    Revenue  

    $

    1,625.1

     

       

    $

    2,222.5

     

     
    Purchase accounting adjustments  

     

    0.6

     

       

     

    0.6

     

     
    Adjusted revenue  

    $

    1,625.7

     

       

    $

    2,223.1

     

     
             
    Adjusted operating income:        
    Operating income  

    $

    553.9

     

     

    34.1

    %

     

    $

    965.7

     

     

    43.4

    %

    Amortization of intangible assets  

     

    95.4

     

     

    5.9

    %

     

     

    107.7

     

     

    4.8

    %

    Purchase accounting adjustments  

     

    1.9

     

     

    0.1

    %

     

     

    9.5

     

     

    0.4

    %

    Asset impairment  

     

    -

     

     

    0.0

    %

     

     

    3.9

     

     

    0.2

    %

    Acquisition and divestiture-related costs  

     

    14.1

     

     

    0.9

    %

     

     

    7.8

     

     

    0.4

    %

    Restructuring and other, net  

     

    3.7

     

     

    0.2

    %

     

     

    3.7

     

     

    0.2

    %

    Adjusted operating income  

    $

    669.0

     

     

    41.1

    %

     

    $

    1,098.2

     

     

    49.4

    %

             
             
    (1) amounts may not sum due to rounding        
    PerkinElmer, Inc. and Subsidiaries
    RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)
     
    Continuing Operations
    Three Months Ended
    October 2, 2022
    Organic revenue growth:
    Reported revenue growth from continuing operations

     

    -17%

     

    Less: effect of foreign exchange rates

     

    -6%

     

    Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

     

    11%

     

    Organic revenue growth from continuing operations

     

    -23%

     

    Less: effect of COVID products

     

    -31%

     

    Non-COVID organic revenue growth from continuing operations

     

    8%

     

     

     

     

     

     

     

    Pro Forma PKI

     

    Three Months Ended

     

     

    October 2, 2022

     

    Pro forma organic revenue growth:

     

     

     

    Reported revenue growth from continuing operations

     

    -17%

     

    Plus: effect of discontinued operations

     

    6%

     

    Less: effect of foreign exchange rates

     

    -6%

     

    Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

     

    8%

     

    Pro forma organic revenue growth

     

    -13%

     

    Less: effect of COVID products

     

    -23%

     

    Pro Forma non-COVID organic revenue growth

     

    9%

     

     

     

     

     

     

     

    DAS

     

    Three Months Ended

     

     

    October 2, 2022

     

    Organic revenue growth:

     

     

     

    Reported revenue growth continuing operations

     

    51%

     

    Less: effect of foreign exchange rates

     

    -5%

     

    Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

     

    42%

     

    Organic revenue growth from continuing operations

     

    14%

     

     

     

     

     

     

     

    Pro Forma DAS

     

    Three Months Ended

     

     

    October 2, 2022

     

    Pro forma organic revenue growth:

     

     

     

    Reported revenue growth from DAS continuing operations

     

    51%

     

    Plus: effect of discontinued operations

     

    -27%

     

    Less: effect of foreign exchange rates

     

    -6%

     

    Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

     

    17%

     

    Pro forma organic revenue growth

     

    12%

     

     

     

     

     

     

     

    Diagnostics

     

    Three Months Ended

     

     

    October 2, 2022

     

    Organic revenue growth:

     

     

     

    Reported revenue growth continuing operations

     

    -39%

     

    Less: effect of foreign exchange rates

     

    -6%

     

    Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

     

    1%

     

    Organic revenue growth from continuing operations

     

    -33%

     

    Less: effect of COVID products

     

    -38%

     

    Non-COVID organic revenue growth from continuing operations

     

    5%

     

     
    (1) amounts may not sum due to rounding

    Explanation of Non-GAAP Financial Measures

    We report our financial results in accordance with GAAP. However, management believes that, in order to more fully understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash, non-recurring or other items, which result from facts and circumstances that vary in frequency and impact on continuing operations. Accordingly, we present non-GAAP financial measures as a supplement to the financial measures we present in accordance with GAAP. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by adjusting for certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management's ability to make useful forecasts. Management believes these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors.

    We use the term "adjusted revenue" to refer to GAAP revenue, including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term "adjusted revenue growth" to refer to the measure of comparing current period adjusted revenue with the corresponding period of the prior year.

    We use the term "pro forma adjusted revenue" to refer to GAAP revenue, including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules and including revenue from the AES business reported in discontinued operations. We use the related term "pro forma adjusted revenue growth" to refer to the measure of comparing current period pro forma adjusted revenue with the corresponding period of the prior year.

    We use the term "organic revenue" to refer to GAAP revenue, excluding the effect of foreign currency changes and revenue from recent acquisitions and divestitures and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term "organic revenue growth" to refer to the measure of comparing current period organic revenue with the corresponding period of the prior year. We use the related term "non-COVID organic revenue growth" to refer to the measure of comparing current period organic revenue excluding revenue from COVID related products and services with the corresponding period of the prior year excluding revenue from COVID related products and services.

    We use the term "pro forma organic revenue" to refer to GAAP revenue, excluding the effect of foreign currency changes and revenue from recent acquisitions and divestitures and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules and including revenue from the AES business reported in discontinued operations. We use the related term "organic revenue growth" to refer to the measure of comparing current period organic revenue with the corresponding period of the prior year. We use the related term "pro forma non-COVID organic revenue growth" to refer to the measure of comparing current period organic revenue excluding revenue from COVID related products and services with the corresponding period of the prior year excluding revenue from COVID related products and services.

    We use the term "adjusted gross margin" to refer to GAAP gross margin, excluding amortization of intangible assets and inventory fair value adjustments related to business acquisitions, asset impairments, and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to business combination accounting rules. We use the related term "adjusted gross margin percentage" to refer to adjusted gross margin as a percentage of adjusted revenue.

    We use the term "pro forma adjusted gross margin" to refer to GAAP gross margin, adjusted for the inclusion of the AES business reported in discontinued operations and including the depreciation of long-lived assets that is ceased upon reporting the business as held for sale. Additional adjustments include: excluding amortization of intangible assets and inventory fair value adjustments related to business acquisitions, asset impairments, and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to business combination accounting rules. We use the related term "pro forma adjusted gross margin percentage" to refer to pro forma adjusted gross margin as a percentage of pro forma adjusted revenue.

    We use the term "adjusted SG&A expense" to refer to GAAP SG&A expense, excluding amortization of intangible assets, purchase accounting adjustments, acquisition and divestiture-related expenses, acceleration of executive compensation, significant litigation matters and settlements, asset impairments, and significant environmental charges. We use the related term "adjusted SG&A percentage" to refer to adjusted SG&A expense as a percentage of adjusted revenue.

    We use the term "pro forma adjusted SG&A expense" to refer to GAAP SG&A expense, adjusted for the inclusion of the AES business reported in discontinued operations and including the depreciation of long-lived assets that is ceased upon reporting the business as held for sale. Additional adjustments include: excluding amortization of intangible assets, purchase accounting adjustments, acquisition and divestiture-related expenses, acceleration of executive compensation, significant litigation matters and settlements, asset impairments, and significant environmental charges. We use the related term "pro forma adjusted SG&A percentage" to refer to pro forma adjusted SG&A expense as a percentage of pro forma adjusted revenue.

    We use the term "adjusted R&D expense" to refer to GAAP R&D expense, excluding amortization of intangible assets and purchase accounting adjustments. We use the related term "adjusted R&D percentage" to refer to adjusted R&D expense as a percentage of adjusted revenue.

    We use the term "pro forma adjusted R&D expense" to refer to GAAP R&D expense, adjusted for the inclusion of the AES business reported in discontinued operations and including the depreciation of long-lived assets that is ceased upon reporting the business as held for sale. Additional adjustments include: excluding amortization of intangible assets and purchase accounting adjustments. We use the related term "pro forma adjusted R&D percentage" to refer to pro forma adjusted R&D expense as a percentage of pro forma adjusted revenue.

    We use the term "adjusted net interest and other expense" to refer to GAAP net interest and other expense, excluding adjustments for mark-to-market accounting on post-retirement benefits, changes in the value of financial securities and debt extinguishment costs.

    We use the term "adjusted operating income," to refer to GAAP operating income, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding amortization of intangible assets, other purchase accounting adjustments, acquisition and divestiture-related expenses, acceleration of executive compensation, significant litigation matters and settlements, significant environmental charges, asset impairments, and restructuring and other charges. We use the related terms "adjusted operating profit percentage," "adjusted operating profit margin," or "adjusted operating margin" to refer to adjusted operating income as a percentage of adjusted revenue.

    We use the term "pro forma adjusted operating income," to refer to GAAP operating income, adjusted for the inclusion of the AES business reported in discontinued operations and including the depreciation of long-lived assets that is ceased upon reporting the business as held for sale. Additional adjustments include: including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding amortization of intangible assets, other purchase accounting adjustments, acquisition and divestiture-related expenses, acceleration of executive compensation, significant litigation matters and settlements, significant environmental charges, asset impairments, and restructuring and other charges. We use the related terms "pro forma adjusted operating profit percentage," "pro forma adjusted operating profit margin," or "pro forma adjusted operating margin" to refer to pro forma adjusted operating income as a percentage of pro forma adjusted revenue.

    We use the term "adjusted earnings per share," or "adjusted EPS," to refer to GAAP earnings per share, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding discontinued operations, amortization of intangible assets, debt extinguishment costs, other purchase accounting adjustments, acquisition and divestiture-related expenses, acceleration of executive compensation, significant litigation matters and settlements, significant environmental charges, changes in the value of financial securities, disposition of businesses and assets, net, asset impairments and restructuring and other charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate this non-GAAP measure. We also adjust for any tax impact related to the above items and exclude the impact of significant tax events.

    We use the term "pro forma adjusted earnings per share," or "pro forma adjusted EPS," to refer to GAAP earnings per share, adjusted for the inclusion of the AES business reported in discontinued operations and including the depreciation of long-lived assets that is ceased upon reporting the business as held for sale. Additional adjustments include: including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding discontinued operations, amortization of intangible assets, debt extinguishment costs, other purchase accounting adjustments, acquisition and divestiture-related expenses, acceleration of executive compensation, significant litigation matters and settlements, significant environmental charges, changes in the value of financial securities, disposition of businesses and assets, net, asset impairments and restructuring and other charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate this non-GAAP measure. We also adjust for any tax impact related to the above items and exclude the impact of significant tax events.

    Management includes or excludes the effect of each of the items identified below in the applicable non-GAAP financial measure referenced above for the reasons set forth below with respect to that item:

    • Amortization of intangible assets—purchased intangible assets are amortized over their estimated useful lives and generally cannot be changed or influenced by management after the acquisition. Accordingly, this item is not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.
    • Debt extinguishment costs—we incur costs and income related to the extinguishment of debt; including make-whole payments to debt holders, accelerated amortization of debt fees and discounts, and expense or income from hedges to lock in make-whole payments. We exclude the impact of these items from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations.
    • Revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules—accounting rules require us to account for the fair value of revenue from contracts assumed in connection with our acquisitions. As a result, our GAAP results reflect the fair value of those revenues, which is not the same as the revenue that otherwise would have been recorded by the acquired entity. We include such revenue in our non-GAAP measures because we believe the fair value of such revenue does not accurately reflect the performance of our ongoing operations for the period in which such revenue is recorded.
    • Other purchase accounting adjustments—accounting rules require us to adjust various balance sheet accounts, including inventory, fixed assets and deferred rent balances to fair value at the time of the acquisition. As a result, the expenses for these items in our GAAP results are not the same as what would have been recorded by the acquired entity. Accounting rules also require us to estimate the fair value of contingent consideration at the time of the acquisition, and any subsequent changes to the estimate or payment of the contingent consideration and purchase accounting adjustments are charged to expense or income. We exclude the impact of any changes to contingent consideration from our non-GAAP measures because we believe these expenses or benefits do not accurately reflect the performance of our ongoing operations for the period in which such expenses or benefits are recorded.
    • Acquisition and divestiture-related expenses—we incur legal, due diligence, stay bonuses, incentive awards, stock-based compensation, interest expense, foreign exchange gains and losses, integration expenses and other costs related to acquisitions and divestitures. We exclude these expenses from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations.
    • Asset impairments—we incur expense related to asset impairments. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.
    • Acceleration of executive compensation—the announced retirement of a senior executive resulted in an acceleration of compensation expense. We exclude these expenses from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations.
    • Restructuring and other charges—restructuring and other charges consist of employee severance, other exit costs as well as the cost of terminating certain lease agreements or contracts as well as costs associated with relocating facilities. Management does not believe such costs accurately reflect the performance of our ongoing operations for the period in which such costs are reported.
    • Adjustments for mark-to-market accounting on post-retirement benefits—we exclude adjustments for mark-to-market accounting on post-retirement benefits, and therefore only our projected costs are used to calculate our non-GAAP measures. We exclude these adjustments because they do not represent what we believe our investors consider to be costs of producing our products, investments in technology and production, and costs to support our internal operating structure.
    • Significant litigation matters and settlements—we incur expenses related to significant litigation matters, including the costs to settle or resolve various claims and legal proceedings. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.
    • Significant environmental charges—we incur expenses related to significant environmental charges. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.
    • Disposition of businesses and assets, net—we exclude the impact of gains or losses from the disposition of businesses and assets from our adjusted earnings per share. Management does not believe such gains or losses accurately reflect the performance of our ongoing operations for the period in which such gains or losses are reported.
    • Impact of foreign currency changes on the current period—we exclude the impact of foreign currency from these measures by using the prior period's foreign currency exchange rates for the current period because foreign currency exchange rates are subject to volatility and can obscure underlying trends.
    • Impact of significant tax events—we exclude the impact of significant tax events, such as the Tax Cuts and Jobs Act of 2017. Management does not believe the impact of significant tax events accurately reflects the performance of our ongoing operations for the periods in which the impact of such events was recorded.
    • Changes in value of financial securities—we exclude the impact of changes in the value of financial securities. Management does not believe such gains or losses accurately reflect the performance of our ongoing operations for the period in which such gains or losses are reported.
    • Inclusion of the AES business in pro forma information—we report the results of the AES business in discontinued operations and include those results as a component of pro forma information. Management believes that including the results of the AES business in discontinued operations as a component of pro forma information increases the comparability of the financial results with historically presented results as well as recent forecasts.
    • Depreciation of fixed assets ceased upon reporting the business as held for sale—we exclude the impact of ceasing depreciation of fixed assets that are held for sale. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such expenses were ceased.

    The tax effect for discontinued operations is calculated based on the authoritative guidance in the Financial Accounting Standards Board's Accounting Standards Codification 740, Income Taxes. The tax effect for amortization of intangible assets, inventory fair value adjustments related to business acquisitions, changes to the fair values assigned to contingent consideration, debt extinguishment costs, other costs related to business acquisitions and divestitures, acceleration of executive compensation, significant litigation matters and settlements, significant environmental charges, changes in the fair value of financial securities, adjustments for mark-to-market accounting on post-retirement benefits, disposition of businesses and assets, net, restructuring and other charges, and the revenue from contracts acquired with various acquisitions is calculated based on operational results and applicable jurisdictional law, which contemplates tax rates currently in effect to determine our tax provision. The tax effect for the impact from foreign currency exchange rates on the current period is calculated based on the average rate currently in effect to determine our tax provision.

    The non-GAAP financial measures described above are not meant to be considered superior to, or a substitute for, our financial statements prepared in accordance with GAAP. There are material limitations associated with non-GAAP financial measures because they exclude charges that have an effect on our reported results and, therefore, should not be relied upon as the sole financial measures by which to evaluate our financial results. Management compensates and believes that investors should compensate for these limitations by viewing the non-GAAP financial measures in conjunction with the GAAP financial measures. In addition, the non-GAAP financial measures included in this earnings announcement may be different from, and therefore may not be comparable to, similar measures used by other companies.

    Each of the non-GAAP financial measures listed above is also used by our management to evaluate our operating performance, communicate our financial results to our Board of Directors, benchmark our results against our historical performance and the performance of our peers, evaluate investment opportunities including acquisitions and discontinued operations, and determine the bonus payments for senior management and employees.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20221108005052/en/

    Get the next $PKI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PKI

    DatePrice TargetRatingAnalyst
    12/19/2022$170.00Sector Weight → Overweight
    KeyBanc Capital Markets
    12/12/2022$135.00 → $170.00Neutral → Buy
    Citigroup
    12/6/2022$192.00 → $164.00Market Perform → Outperform
    Cowen
    11/28/2022$130.00 → $145.00Underweight → Equal Weight
    Barclays
    8/25/2022$175.00Neutral
    Credit Suisse
    8/18/2022$190.00 → $170.00Buy → Hold
    Stifel
    8/2/2022$178.00Buy → Neutral
    BofA Securities
    7/20/2022$160.00Buy
    UBS
    More analyst ratings

    $PKI
    Financials

    Live finance-specific insights

    See more
    • Revvity Announces Financial Results for the First Quarter of 2023

      Revenue of $675 million; (30)% reported growth; (27)% organic growth; 6% non-COVID organic growth GAAP EPS of $4.50; Adjusted EPS from continuing operations of $1.01 Updates full year 2023 guidance Authorizes new $600 million share repurchase program To begin trading under new ticker "RVTY" on May 16th Revvity, Inc. (NYSE:PKI), today reported financial results for the first quarter ended April 2, 2023. The Company reported GAAP earnings per share of $4.50, as compared to $1.40 in the same period a year ago. GAAP revenue for the quarter was $675 million, as compared to $963 million in the same period a year ago. GAAP operating income for the quarter was $76 million, as comp

      5/11/23 6:00:00 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Launching Revvity: A Scientific Solutions Company Powering Innovation from Discovery to Cure

       Transformation aimed at revolutionizing next generation scientific breakthroughs that solve the world's greatest health challenges Trusted partner to pharma, government and diagnostics customers with complete, end-to-end solutions To begin trading as RVTY under new name on May 16th (NYSE:PKI) Revvity, Inc. officially launches today as a science-based solutions company that leverages innovation across life sciences and diagnostics to help improve lives everywhere. Born from two words, "revolutionize" (rev) and "vita" (vit) meaning "life" in Latin, Revvity delivers end-to-end expertise and solutions from research discovery to development, and diagnosis to cure. The Company was prev

      5/9/23 8:00:00 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PerkinElmer Board Declares Quarterly Dividend

      The Board of Directors of PerkinElmer, Inc. (NYSE:PKI) today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 11, 2023 to all shareholders of record at the close of business on July 21, 2023. About The PerkinElmer Life Sciences and Diagnostics Company The PerkinElmer Life Sciences and Diagnostics company – which is to be renamed during the second quarter of 2023 – provides end-to-end solutions that help scientists, researchers and clinicians better diagnose disease and discover new and more personalized drugs. The Company reported revenues of approximately $3.3 billion in 2022, serves customers in 190 countries, and is a compon

      4/25/23 4:05:00 PM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PKI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Revvity Announces Financial Results for the First Quarter of 2023

      Revenue of $675 million; (30)% reported growth; (27)% organic growth; 6% non-COVID organic growth GAAP EPS of $4.50; Adjusted EPS from continuing operations of $1.01 Updates full year 2023 guidance Authorizes new $600 million share repurchase program To begin trading under new ticker "RVTY" on May 16th Revvity, Inc. (NYSE:PKI), today reported financial results for the first quarter ended April 2, 2023. The Company reported GAAP earnings per share of $4.50, as compared to $1.40 in the same period a year ago. GAAP revenue for the quarter was $675 million, as compared to $963 million in the same period a year ago. GAAP operating income for the quarter was $76 million, as comp

      5/11/23 6:00:00 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Launching Revvity: A Scientific Solutions Company Powering Innovation from Discovery to Cure

       Transformation aimed at revolutionizing next generation scientific breakthroughs that solve the world's greatest health challenges Trusted partner to pharma, government and diagnostics customers with complete, end-to-end solutions To begin trading as RVTY under new name on May 16th (NYSE:PKI) Revvity, Inc. officially launches today as a science-based solutions company that leverages innovation across life sciences and diagnostics to help improve lives everywhere. Born from two words, "revolutionize" (rev) and "vita" (vit) meaning "life" in Latin, Revvity delivers end-to-end expertise and solutions from research discovery to development, and diagnosis to cure. The Company was prev

      5/9/23 8:00:00 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Ares Management Corporation Announces U.S. Direct Lending Origination Activity for the First Quarter and Last Twelve Months 2023

      Approximately $2.1 Billion in New Commitments Closed in the First Quarter and Approximately $23.5 Billion closed in the Last Twelve Months Ended March 31, 2023 Ares Management Corporation announced today that funds managed by its Credit Group (collectively "Ares") closed approximately $2.1 billion in U.S. direct lending commitments across 35 transactions during the first quarter of 2023 and approximately $23.5 billion in U.S. direct lending commitments across 189 transactions in the last twelve-month period ended March 31, 2023. Below is a description of selected transactions that Ares closed during the first quarter. Banyan Software Ares served as the agent, lead arranger and bookrun

      4/28/23 6:30:00 AM ET
      $ARES
      $PKI
      Investment Managers
      Finance
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PKI
    SEC Filings

    See more
    • PerkinElmer Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - REVVITY, INC. (0000031791) (Filer)

      2/1/24 6:05:15 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PerkinElmer Inc. filed SEC Form 8-K: Leadership Update

      8-K - REVVITY, INC. (0000031791) (Filer)

      1/26/24 8:00:33 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PerkinElmer Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - REVVITY, INC. (0000031791) (Filer)

      1/9/24 8:05:29 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PKI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)

      SC 13G/A - REVVITY, INC. (0000031791) (Subject)

      2/14/24 4:11:39 PM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)

      SC 13G/A - REVVITY, INC. (0000031791) (Subject)

      2/14/24 10:04:34 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)

      SC 13G/A - REVVITY, INC. (0000031791) (Subject)

      2/13/24 5:13:53 PM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PKI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • PerkinElmer upgraded by KeyBanc Capital Markets with a new price target

      KeyBanc Capital Markets upgraded PerkinElmer from Sector Weight to Overweight and set a new price target of $170.00

      12/19/22 7:48:08 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PerkinElmer upgraded by Citigroup with a new price target

      Citigroup upgraded PerkinElmer from Neutral to Buy and set a new price target of $170.00 from $135.00 previously

      12/12/22 7:52:36 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PerkinElmer upgraded by Cowen with a new price target

      Cowen upgraded PerkinElmer from Market Perform to Outperform and set a new price target of $164.00 from $192.00 previously

      12/6/22 7:47:47 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PKI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Gonzales Anita covered exercise/tax liability with 119 shares, decreasing direct ownership by 3% to 3,591 units (SEC Form 4)

      4 - REVVITY, INC. (0000031791) (Issuer)

      2/16/24 5:33:35 PM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Krakowiak Maxwell covered exercise/tax liability with 85 shares, decreasing direct ownership by 1% to 7,117 units (SEC Form 4)

      4 - REVVITY, INC. (0000031791) (Issuer)

      2/16/24 5:09:03 PM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Klobuchar Michael A was granted 481 shares (SEC Form 4)

      4 - REVVITY, INC. (0000031791) (Issuer)

      2/16/24 4:05:16 PM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PKI
    Leadership Updates

    Live Leadership Updates

    See more
    • James Mock Joins Moderna as Chief Financial Officer

      CAMBRIDGE, MA / ACCESSWIRE / August 17, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that James Mock has been appointed as Moderna's Chief Financial Officer, beginning September 6, 2022. He will serve on Moderna's Executive Committee and report to Chief Executive Officer Stéphane Bancel. Following the appointment of Mr. Mock, David Meline will retire as the Company's CFO effective the same date but will remain as a consultant to the Company to assist with the transition."I am thrilled to welcome Jamey to Moderna's Executive Committee as our Chief Financial Officer. Moderna is at an exciting stage with a

      8/17/22 8:00:00 AM ET
      $MRNA
      $PKI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PerkinElmer Announces Finance Leadership Transition

      Max Krakowiak appointed new chief financial officer, replacing Jamey Mock PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that Senior Vice President and Chief Financial Officer Jamey Mock will be transitioning from the Company to pursue an outside opportunity. The Company's Board of Directors has unanimously appointed Max Krakowiak to succeed Mr. Mock as its new senior vice president and CFO, effective as of September 6, 2022. Mr. Krakowiak is currently the Company's vice president of corporate finance, and has served in financial leadership roles of increasing responsibility for the last four years. "I would like to thank Jamey

      8/17/22 8:00:00 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PerkinElmer Provides First Quarter Update and Schedules Earnings Call for Tuesday, May 4, 2021

       Company also announces appointment of Steve Willoughby as vice president, investor relations PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates reported and organic revenue growth of 98% and 90%, respectively, for the first quarter ended April 4, 2021. PerkinElmer's strong revenue performance was driven by broad-based momentum across the portfolio. In total, non-COVID-19, or core, demand increased approximately 10% organically year-over-year, and COVID-19 related solutions contributed approximately $535 million of revenue in the first quarter. PerkinElmer will release its first quarter 2021 financial results a

      4/13/21 4:15:00 PM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials